1. Ashmarin I.P. 2007. Glyprolines in regulatory tripeptides. Neurochem. J. 1, 173–175.
2. Ashmarin I.P., Samonina G.E., Lyapina L.A., Kamenskii A.A., Levitskaya N.G., Grivennikov I.A., Dolotov O.V., Andreeva L.A., Myasoedov N.F. 2005. Natural and hybrid (“chimeric”) stable regulatory glyproline peptides. Pathophysiology. 11, 179–185.
3. Zozulya A.A., Neznamov G.G., Syunyakov T.S., Kost N.V., Gabaeva M.V., Sokolov O.I., Serebryakova E.V., Siranchieva O.A., Andryushenko A.V., Telesheva E.S., Syunyakov S.A., Smulevich A.B., Myasoedov N.F., Seredenin S.B. 2008. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh. Nevrol. Psikhiatr. im. S.S. Korsakova. 108, 38–48.
4. Kaplan A.I., Koshelev V.B., Nezavibat’ko V.N., Ashmarin I.P. 1992. Increased resistance to hypoxia effected by the neuropeptide preparation SEMAX. Fiziol. Cheloveka. 18, 104–107.
5. Storozhevykh T.P., Tukhbatova G.R., Senilova Ya.E., Pinelis V.G., Andreeva L.A., Myasoyedov N.F. 2007. Effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bull. Exp. Biol. Med. 143, 601–604.